title: Aromatase inhibitors as adjuvant therapy for breast cancer: overall survival versus disease-free survival as a primary end point in clinical practice.
authors.forename: Alfonso
authors.initials: A
authors.lastname: Sánchez-Muñoz
authors.forename: Nuria
authors.initials: N
authors.lastname: Ribelles
authors.forename: Antonia
authors.initials: A
authors.lastname: Márquez
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Pérez-Ruiz
authors.forename: Emilio
authors.initials: E
authors.lastname: Alba
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D018579:Patient Selection; D016019:Survival Analysis; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen